genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Graphite Bio
Genome Editing
FDA Approves the First CRISPR Therapy for Sickle Cell Disease
Drug Discovery
A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results
Drug Discovery
Graphite Erased: LENZ to Merge with Gene Editing Therapy Developer
Genome Editing
Sanofi, Scribe Launch Up-to-$1.2B Collaboration in SCD, Genomic Diseases
Genome Editing
Anticipating ASGCT with Terry Flotte
Drug Discovery
Lightspeed’s Jonathan MacQuitty and the Laws of Biotech Relativity
GEN Edge
Hit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial Suspension
GEN Edge
Can Graphite Bio Realize the Promise of CRISPR Gene Editing to Develop One-Time Cures?
Scroll Up
Scroll Up
